Forest Sees “Moderate” Namenda Growth Opportunity In Mild Alzheimer’s
Executive Summary
Forest expects approval of its Namenda sNDA for the treatment of mild-to-moderate Alzheimer's disease to generate a "modest uptick" in prescription volume in the second half of the year